Results 281 to 290 of about 4,051,827 (361)
Facilitators to doctoral completion among international students in a Global South University: An appreciative inquiry perspective. [PDF]
Zhang S, Zhan H.
europepmc +1 more source
Language Models for Code Completion: A Practical Evaluation [PDF]
Maliheh Izadi +5 more
openalex +1 more source
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Factors influencing the completion of advance directives in cancer patients: a descriptive survey. [PDF]
Hwang W, Do J.
europepmc +1 more source
Parental Perceptions of Dental Care Utilisation and Their Association With Treatment Completion, Follow‐Up and Children's Quality of Life: A Cross‐Sectional Study [PDF]
Dania Bahdila
openalex +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
SRS SWPF Construction Completion
Jack Craig, Frank Sheppard, Pam Marks
openalex +1 more source

